Cargando…

P- 35 RELINKAGE OF PATIENTS WITH CHRONIC HEPATITIS C INFECTION IN THE CONTEXT OF THE COVID-19 PANDEMIC

INTRODUCTION AND OBJECTIVES: In Argentina, it is estimated that around 50% of patients infected with hepatitis C virus (HCV) have been diagnosed and only 5% of those have accessed treatment after several months; this reality got worse with the pandemic. World Health Organization proposed a global he...

Descripción completa

Detalles Bibliográficos
Autores principales: Sotera, Gisela Fabiana, Ferreiro, Melina, Martes, Margarita, Nancy, Cordero, Salmon, Jonathan, Sordá, Juan, Daruich, Jorge, Ballerga, Esteban González
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier España, S.L. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030174/
http://dx.doi.org/10.1016/j.aohep.2023.100937
Descripción
Sumario:INTRODUCTION AND OBJECTIVES: In Argentina, it is estimated that around 50% of patients infected with hepatitis C virus (HCV) have been diagnosed and only 5% of those have accessed treatment after several months; this reality got worse with the pandemic. World Health Organization proposed a global health sector strategy to eliminate HCV as a public health threat by 2030. Key elements of the elimination plan include increased diagnosis and treatment access. This study aimed to describe the implementation of “Relinkage and simplified care pathway program” as a strategy for micro-elimination of HCV. MATERIALS AND METHODS: : Hospital outpatients aged over 18 years, with a confirmed or suspected diagnosis of HCV infection and without follow-up during the last year, were included.  Patient selection was made by collecting data from medical records. Selected patients were contacted by telephone and scheduled for a clinic visit with a simplified care pathway. “Reflex Testing,” which is an HCV antibody test, was used; if the result was positive, an HCV RNA and genotype test on the same specimen was performed. Untreated and non-responder patients were treated. RESULTS: : A total of 938 patients were included, and 409 (44%) could be reached. Out Of these, 16.3% (67) died, 1.7% (7) developed hepatocellular carcinoma, and 6.75% (15) progressed to cirrhosis. We found that 21.7% were candidates for treatment, and the treatment was delivered in two clinic visits with an average time of 29 days (7-69). However, 41% (34) of patients with cirrhosis could not be contacted. CONCLUSIONS: : Program implementation improved the diagnosis and treatment access. Furthermore, it reduces the number of clinical visits and may increase adherence to follow-up. On the other hand, we are concerned that half of the patients were lost on the follow-up and about their progression to cirrhosis rate. If we are looking for different results, we should take different measures.